Pathstone Holdings
GSK icon

Pathstone Holdings’s GSK GSK Stock Holding History

Pathstone Holdings’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.82M Buy
91,733
+1,972
+2% +$104K 0.01% 660
2026
Q1 		$4.96M Buy
89,761
+13,783
+18% +$747K 0.02% 572
2025
Q4 		$3.73M Sell
75,978
-164,102
-68% -$7.65M 0.01% 687
2025
Q3 		$10.4M Buy
240,080
+1,089
+0.5% +$42.5K 0.04% 326
2025
Q2 		$9.15M Sell
238,991
-10,672
-4% -$408K 0.04% 352
2025
Q1 		$9.68M Sell
249,663
-7,052
-3% -$258K 0.04% 352
2024
Q4 		$8.69M Buy
256,715
+10,101
+4% +$364K 0.04% 364
2024
Q3 		$10.1M Buy
246,614
+26,707
+12% +$1.09M 0.04% 313
2024
Q2 		$8.47M Buy
219,907
+6,773
+3% +$285K 0.04% 354
2024
Q1 		$9.14M Buy
213,134
+17,592
+9% +$725K 0.04% 321
2023
Q4 		$7.25M Buy
+195,542
New +$7.02M 0.04% 334

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Pathstone Holdings's GSK Position: Q2 2026 in Review

Pathstone Holdings increased its GSK (GSK) stake by 2.2% in Q2 2026, buying an estimated $104K and bringing the position to 91,733 shares worth $4.82M. The position accounts for 0.01% of the portfolio, ranked #660.

Pathstone Holdings first reported a position in GSK in Q4 2023 and has held it in 11 quarters since. The position peaked at $10.4M in Q3 2025. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Pathstone Holdings held 91,733 shares of GSK worth $4.82M as of Q2 2026.
  • Pathstone Holdings bought 1,972 GSK shares in Q2 2026, an estimated $104K.
  • GSK made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #660 holding.
  • Pathstone Holdings first reported a position in GSK in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's GSK position peaked at $10.4M in Q3 2025.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.